When people lose the same amount of weight through either GLP-1 receptor agonists or calorie restriction, the drugs cause different changes in muscle proteins related to energy production and protein...
Mechanism
Synthesis from 1 study
Even when people lose the same weight by dieting or taking the drug, the drug makes muscle cells build better energy factories and clean up damaged parts better than dieting alone. This helps muscles work harder and longer, even if they get a little smaller.
Most probable mechanism
Even when people or mice lose the same amount of weight by eating less or taking a GLP-1 drug, the drug makes muscle cells produce more energy-making parts and clean up damaged proteins better than dieting alone. This helps muscles work longer without getting tired and stay stronger despite losing some mass.
GLP-1 receptor agonists activate signaling pathways in skeletal muscle that increase expression of mitochondrial proteins involved in energy production, despite the absence of functional GLP-1 receptors on muscle cells themselves
Upregulation of mitochondrial respiratory chain components enhances aerobic capacity and ATP production efficiency in muscle fibers
GLP-1 receptor agonists increase expression of proteasome core subunits and chaperone proteins in skeletal muscle under catabolic stress
Enhanced proteasome activity promotes clearance of damaged proteins and upregulates myogenic regulators that support muscle repair
Improved mitochondrial function and proteostasis collectively enhance muscle endurance, delay fatigue, and preserve relative muscle strength during weight loss
Less supported by current evidence, but not ruled out
The drug causes more fat and liver tissue to shrink than muscle, so even if muscle gets slightly smaller, it has less weight to move around — making it feel stronger and more efficient.
GLP-1 receptor agonists activate hepatic receptors to increase fatty acid oxidation and glycogen depletion, leading to greater reduction in liver mass compared to skeletal muscle
GLP-1 receptor agonists reduce white adipose tissue mass by increasing lipolysis and suppressing lipogenesis
Greater loss of adipose and liver tissue relative to muscle mass increases the proportion of muscle to total body weight
Reduced total body weight lowers the mechanical load on skeletal muscle, improving power-to-weight ratio and endurance performance
Evidence from Studies
Supporting (1)
Community contributions welcome
Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.